CHINOOK THERAPEUTICS, INC.
Total Trades
64
Buys
3
Sells
33
Largest Trade
N/A
Insiders
11
Institutional Funds
2
Inst. Value
N/A
Activist Filings
15
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| King Andrew James | Chief Scientific O… | SELL | $15K–$50K | 1K | $39.03 | Aug 1, 2023 |
| King Andrew James | Chief Scientific O… | EXERCISE | N/A | 3K | — | Aug 1, 2023 |
| Greenman William Mariner | Director | EXERCISE | N/A | 3K | — | May 31, 2023 |
| Greenman William Mariner | Director | SELL | $15K–$50K | 1K | $23.30 | May 31, 2023 |
| DOBMEIER ERIC | President, CEO | EXERCISE | $1K–$15K | 25K | $0.42 | Apr 26, 2023 |
| DOBMEIER ERIC | President, CEO | SELL | $500K+ | 25K | $21.61 | Apr 26, 2023 |
| Jerel Davis | Director | SELL | $1M+ | 296K | $20.75 | Apr 19, 2023 |
| King Andrew James | Chief Scientific O… | SELL | $100K–$500K | 5K | $23.34 | Apr 5, 2023 |
| King Andrew James | Chief Scientific O… | EXERCISE | <$1K | 3K | $0.35 | Apr 5, 2023 |
| Krishnan Mahesh | Director | EXERCISE | N/A | 2K | — | Apr 5, 2023 |
| Krishnan Mahesh | Director | SELL | $15K–$50K | 924 | $23.01 | Apr 5, 2023 |
| Jerel Davis | Director | SELL | $1M+ | 400K | $22.75 | Mar 3, 2023 |
| BJERKHOLT ERIC | CFO | SELL | $15K–$50K | 857 | $23.75 | Feb 15, 2023 |
| BJERKHOLT ERIC | CFO | EXERCISE | N/A | 2K | — | Feb 15, 2023 |
| DOBMEIER ERIC | President, CEO | SELL | $100K–$500K | 8K | $23.75 | Feb 15, 2023 |
| DOBMEIER ERIC | President, CEO | EXERCISE | N/A | 20K | — | Feb 15, 2023 |
| Frohlich Tom | COO | SELL | $50K–$100K | 4K | $23.75 | Feb 15, 2023 |
| Frohlich Tom | COO | EXERCISE | N/A | 7K | — | Feb 15, 2023 |
| King Andrew James | Chief Scientific O… | SELL | $50K–$100K | 2K | $23.75 | Feb 15, 2023 |
| King Andrew James | Chief Scientific O… | EXERCISE | N/A | 7K | — | Feb 15, 2023 |
| Frohlich Tom | COO | SELL | $100K–$500K | 5K | $24.68 | Feb 2, 2023 |
| Frohlich Tom | COO | EXERCISE | N/A | 8K | — | Feb 2, 2023 |
| BJERKHOLT ERIC | CFO | SELL | $50K–$100K | 3K | $24.68 | Feb 2, 2023 |
| BJERKHOLT ERIC | CFO | EXERCISE | N/A | 7K | — | Feb 2, 2023 |
| King Andrew James | Chief Scientific O… | SELL | $50K–$100K | 3K | $24.68 | Feb 2, 2023 |
| King Andrew James | Chief Scientific O… | EXERCISE | N/A | 8K | — | Feb 2, 2023 |
| DOBMEIER ERIC | President, CEO | EXERCISE | $1K–$15K | 50K | $0.21 | Feb 2, 2023 |
| DOBMEIER ERIC | President, CEO | SELL | $500K+ | 33K | $24.58 | Feb 2, 2023 |
| King Andrew James | Chief Scientific O… | EXERCISE | $1K–$15K | 8K | $0.35 | Jan 5, 2023 |
| King Andrew James | Chief Scientific O… | SELL | $100K–$500K | 10K | $25.82 | Jan 5, 2023 |
| Frohlich Tom | COO | EXERCISE | $1K–$15K | 10K | $0.42 | Dec 15, 2022 |
| Frohlich Tom | COO | SELL | $100K–$500K | 10K | $25.00 | Dec 15, 2022 |
| DOBMEIER ERIC | President, CEO | SELL | $500K+ | 30K | $22.31 | Dec 2, 2022 |
| DOBMEIER ERIC | President, CEO | EXERCISE | $15K–$50K | 60K | $0.42 | Dec 2, 2022 |
| BJERKHOLT ERIC | CFO | EXERCISE | N/A | 16K | — | Dec 2, 2022 |
| BJERKHOLT ERIC | CFO | SELL | $100K–$500K | 6K | $22.29 | Dec 2, 2022 |
| Frohlich Tom | COO | EXERCISE | $1K–$15K | 10K | $0.42 | Nov 9, 2022 |
| Frohlich Tom | COO | SELL | $100K–$500K | 10K | $22.16 | Nov 9, 2022 |
| Frohlich Tom | COO | SELL | $100K–$500K | 7K | $19.69 | Oct 11, 2022 |
| Frohlich Tom | COO | EXERCISE | N/A | 14K | — | Oct 11, 2022 |
| King Andrew James | Chief Scientific O… | EXERCISE | N/A | 10K | — | Oct 11, 2022 |
| King Andrew James | Chief Scientific O… | SELL | $50K–$100K | 4K | $19.69 | Oct 11, 2022 |
| Thomas Dolca | Director | BUY | $100K–$500K | 10K | $21.22 | Sep 6, 2022 |
| King Andrew James | Chief Scientific O… | EXERCISE | $1K–$15K | 5K | $0.35 | Aug 5, 2022 |
| King Andrew James | Chief Scientific O… | SELL | $100K–$500K | 5K | $20.00 | Aug 5, 2022 |
| King Andrew James | Chief Scientific O… | SELL | $50K–$100K | 5K | $18.09 | Jul 13, 2022 |
| King Andrew James | Chief Scientific O… | EXERCISE | $1K–$15K | 5K | $0.35 | Jul 13, 2022 |
| AKKARAJU SRINIVAS | Director | BUY | $1M+ | 570K | $14.00 | Jun 1, 2022 |
| DOBMEIER ERIC | President, CEO | BUY | $50K–$100K | 5K | $13.03 | May 27, 2022 |
| King Andrew James | Chief Scientific O… | SELL | $50K–$100K | 5K | $15.36 | Apr 13, 2022 |
Institutional Ownership
13F filings as of Mar 31, 2025 · 2 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| Farther Finance Advisors, LLC | 100 | N/A | SH |
| Parallel Advisors, LLC | 5 | N/A | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
SC 13D/A · Nov 22, 2023
0.0%
0 shares
Farallon Capital Partners, L.P.
SC 13D · Aug 11, 2023
1.7%
1.2M shares
Baillie Gifford & Co (Scottish partnership)
SC 13G/A · Aug 1, 2023
2.0%
845K shares
Versant Venture Capital VII, L.P.
SC 13D/A · Mar 10, 2023
3.2%
2.1M shares
Frazier Life Sciences Public Fund, L.P.
SC 13G/A · Feb 14, 2023
4.9%
3.1M shares
SC 13G/A · Feb 14, 2023
4.7%
3.0M shares
SC 13G/A · Feb 1, 2023
6.2%
4.0M shares
Versant Venture Capital VII, L.P.
SC 13D/A · Dec 28, 2022
3.7%
2.3M shares
Versant Venture Capital VII, L.P.
SC 13D/A · Aug 22, 2022
4.6%
2.9M shares
SC 13D · Jun 1, 2022
8.4%
5.2M shares
Frazier Life Sciences Public Fund, L.P.
SC 13G · Apr 29, 2022
3.4%
1.9M shares
Versant Venture Capital VII, L.P.
SC 13D/A · Apr 13, 2022
5.3%
2.9M shares
Morningside Venture (VI) Investments Ltd.
SC 13D/A · Feb 22, 2022
0.0%
0 shares
SC 13G · Feb 16, 2022
5.0%
2.8M shares
ATP Life Science Ventures, L.P.
SC 13G/A · Jan 21, 2022
0.0%
0 shares